Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: from biological evidence to clinical application
M Lambertini, F Horicks, L Del Mastro… - Cancer treatment …, 2019 - Elsevier
Survivorship issues are an area of crucial importance to be addressed as early as possible
by all health care providers dealing with cancer patients. In women diagnosed during their …
by all health care providers dealing with cancer patients. In women diagnosed during their …
Gonadotropin releasing hormone agonists have an anti-apoptotic effect on cumulus cells
P Scaruffi, S Stigliani, B Cardinali, C Massarotti… - International Journal of …, 2019 - mdpi.com
Background: Ovaries are sensitive to chemotherapy, which may lead to early depletion of
primordial follicle reserve. One strategy for gonadal function preservation is temporary …
primordial follicle reserve. One strategy for gonadal function preservation is temporary …
No significant long-term complications from inadvertent exposure to gonadotropin-releasing hormone agonist during early pregnancy in mothers and offspring: a …
H Wu, X Xu, C Ma, Y Zhou, S Pei, H Geng, Y He… - Reproductive Biology …, 2021 - Springer
Background Administration of gonadotropin-releasing hormone agonist (GnRH-a) in the
luteal phase is commonly used for pituitary suppression during in vitro fertilisation (IVF) …
luteal phase is commonly used for pituitary suppression during in vitro fertilisation (IVF) …
[引用][C] Protective mechanisms of triptorelin against tripterygium glycoside-induced ovarian dysfunction.
YC Zhao, L Lv, DS Li, J Zhao, HY Wang - Biomedical Research (0970-938X), 2018